V. Semiglazov

发表

[Results of a prospective randomized investigation [Russia (St.Petersburg)/WHO] to evaluate the significance of self-examination for the early detection of breast cancer].

V. Semiglazov, A. Manikhas, V. Moiseenko, 2003, Voprosy onkologii.

A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy

P. Neven, V. Semiglazov, S. Johnston, 2008, Breast Cancer Research and Treatment.

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

C. Perou, E. Winer, J. Forbes, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer.

H. Mouridsen, V. Semiglazov, V. Harvey, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.

Paolo Morandi, Ana Lluch, A. Lluch, 2016, The Lancet. Oncology.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

J. Cuzick, A. Tutt, C. Denkert, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

More favorable progesterone receptor phenotype of breast cancer in diabetics treated with metformin

V. Semiglazov, L. Berstein, M. P. Boyarkina, 2011, Medical oncology.

The role of digital mammography, scintimammography with 99m Tc-methoxyisobutylisonitrile (MIBI) and ultrasound in the diagnosis of multicentric breast cancer

V. Semiglazov, S. Kanaev, A. Chernaya, 2020, Tumors of female reproductive system.

Clinical trials on adjuvant chemotherapy for breast cancer

V. Semiglazov, R. T. Popova, O. Ivanova, 1986, Cancer.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

E. Winer, J. Cuzick, A. Tutt, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Future prospects for breast cancer immunotherapy

V. Semiglazov, V. Semiglazov, P. Krivorotko, 2018, Medical Council.

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

E. Winer, J. Cuzick, A. Tutt, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: A MICHELANGO study.

V. Semiglazov, L. Gianni, P. Valagussa, 2016 .

A Phase III Randomized Equivalence Study of Biosimilar Filgrastim versus Amgen Filgrastim in Patients Receiving Myelosuppressive Chemotherapy for Breast Cancer

V. Semiglazov, S. Tjulandin, S. Chan, 2010, Oncology Research and Treatment.

Biopsychosocial approach in the rehabilitation of patients with operable breast cancer

A. V. Belyaev, V. Semiglazov, T. Semiglazova, 2020, Meditsinskiy sovet = Medical Council.

A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer.

G. MacBeath, P. Goss, V. Semiglazov, 2014 .

Is the extension of adjuvant hormone therapy for breast cancer justified?

V. Semiglazov, V. S. Apollonova, Владимир Федорович Семиглазов, 2020, Meditsinskiy sovet = Medical Council.

First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study.

M. Espié, N. Bogdanova, V. Semiglazov, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

R. Greil, F. André, V. Semiglazov, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Geographical distribution of breast cancer in the USSR

V. Semiglazov, V. Merabishvili, L. Serova, 1984, International journal of cancer.

The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER- positive breast cancer.

V. Semiglazov, V. Ivanov, V. Semiglazov, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF)

J. Baselga, W. Eiermann, A. Lluch, 2005 .

NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia

P. Devilee, A. Sokolenko, E. Imyanitov, 2005, International journal of cancer.

Signs of proinflammatory/genotoxic switch (adipogenotoxicosis) in mammary fat of breast cancer patients: Role of menopausal status, estrogens and hyperglycemia

V. Semiglazov, L. Berstein, E. Tsyrlina, 2007, International journal of cancer.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial.

V. Semiglazov, V. V. Stepula, A. Dudov, 2006, Anticancer research.

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.

E. Winer, J. Cuzick, A. Tutt, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of two treatment strategies for irradiation of regional lymph nodes in patients with breast cancer: Lymph flow guided portals versus standard radiation fields.

V. Semiglazov, S. Kanaev, S. Novikov, 2015, Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology.

2030 ORAL Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer: data from the NOAH (NeOAdjuvant Herceptin) Phase III trial

J. Baselga, W. Eiermann, A. Lluch, 2007 .

Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer.

A. Buzdar, B. Xu, D. Miles, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast in BRCA1 carrier

A. Sokolenko, E. Imyanitov, V. Semiglazov, 2011, Breast cancer.

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.

Y. Wang, A. Schneeweiss, Ming Yan, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant endocrine therapy for perimenopausal women with early breast cancer.

H. Wildiers, J. Dixon, V. Semiglazov, 2009, Breast.

Eniluracil plus 5-fluorouracil and leucovorin: treatment for metastatic breast cancer patients in whom capecitabine treatment rapidly failed.

Jenny C. Chang, V. Semiglazov, T. Spector, 2014, Clinical breast cancer.

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.

M. Buyse, G. Sauter, J. Mackey, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of metabolic rehabilitation-based approach in TNBC: biguanide metformin and more

V. Semiglazov, L. Berstein, G. Dashyan, 2011 .

EXPERIENCE WITH SUBCUTANEOUS TRASTUZUMAB USED IN RUSSIAN FEDERATION

V. Semiglazov, I. Vorotnikov, N. Savelov, 2017 .

NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER

V. Semiglazov, V. Ivanov, V. Semiglazov, 2018, Siberian journal of oncology.

Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing

A. Sokolenko, E. Imyanitov, V. Semiglazov, 2009, Hereditary cancer in clinical practice.

Hereditary Breast-Ovarian Cancer Syndrome in Russia

A. Sokolenko, E. Imyanitov, V. Semiglazov, 2010, Acta naturae.

Hormone-receptor status and likelihood of predicting pathological complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC)

J. Baselga, W. Eiermann, V. Semiglazov, 2008 .

Trabectedin in third line breast cancer: A multicenter, randomized, phase II study comparing two administration regimens

V. Semiglazov, S. Tjulandin, L. Goldstein, 2005 .

S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC)

R. Greil, F. André, V. Semiglazov, 2011 .

Breast cancer

V. Semiglazov, L. Zavalishina, I. Koroleva, 2021, Journal of Modern Oncology.

Immunology and immunotherapy in the complex treatment of malignant tumors

V. Semiglazov, S. Protsenko, V. Semiglazov, 2021, Meditsinskiy sovet = Medical Council.

Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.

J. Baselga, B. Leyland-Jones, V. Semiglazov, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

Wolfgang Eiermann, Fatima Cardoso, W. Eiermann, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

J. Baselga, W. Eiermann, A. Lluch, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia

P. Devilee, A. Sokolenko, E. Imyanitov, 2007, Familial Cancer.

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

J. Baselga, M. Climent, W. Eiermann, 2010, The Lancet.

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.

L. Pusztai, A. Lluch, V. Semiglazov, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Post-neoadjuvant treatment of breast cancer

V. Semiglazov, P. Krivorotko, R. V. Donskikh, 2020, Meditsinskiy sovet = Medical Council.

High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia

A. Antoniou, A. Sokolenko, E. Imyanitov, 2012, International journal of cancer.

High frequency of BRCA1 5382insC mutation in Russian breast cancer patients.

P. Devilee, A. Sokolenko, E. Imyanitov, 2006, European journal of cancer.

CHEK2 1100delC mutation is frequent among Russian breast cancer patients

P. Devilee, A. Sokolenko, E. Imyanitov, 2006, Breast Cancer Research and Treatment.

Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial

C. Sotiriou, S. Loi, M. Piccart, 2021, Clinical Cancer Research.

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.

J. Baselga, M. Climent, W. Eiermann, 2014, The Lancet. Oncology.

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

R. Greil, J. Baselga, H. Lane, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

J. Baselga, V. Semiglazov, A. Manikhas, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER 2-positive metastatic breast cancer

J. Baselga, V. Semiglazov, A. Manikhas, 2014 .

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

R. Gelber, J. Baselga, U. Dafni, 2011, The Lancet. Oncology.

Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy

J. Baselga, W. Eiermann, A. Lluch, 2005, Clinical Cancer Research.

Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase II

Liang Xiu, N. Bogdanova, J. Sparano, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC).

Sung-Bae Kim, A. Schneeweiss, S. Swain, 2019, Journal of Clinical Oncology.

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor‐positive breast cancer

V. Semiglazov, V. Ivanov, L. Berstein, 2007, Cancer.

Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1–2, T3N0–1, T4N0M0)

V. Semiglazov, L. Berstein, G. Dashyan, 2005 .

[Neoadjuvant systemic therapy for breast cancer].

V. Semiglazov, 2012, Voprosy onkologii.

Neoadjuvant (Preoperative) Therapy in Breast Cancer

V. Semiglazov, V. Semiglazov, 2013 .

1 Neoadjuvant Systemic Therapy in Breast Cancer

V. Semiglazov, V. Semiglazov, 2012 .

a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer

M. Buyse, K. Gelmon, J. Mackey, 2014 .

Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer.

V. Semiglazov, I. K. Seleznev, A. A. Orlov, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial.

J. Jassem, V. Semiglazov, R. Bell, 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

Andreas Makris, Wolfgang Eiermann, Vered Stearns, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

S. Margolin, M. Desilvio, V. Semiglazov, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.

J. Baselga, W. Eiermann, A. Lluch, 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor–Positive Locally Advanced or Metastatic Breast Cancer

G. Acton, N. Ibrahim, J. Murray, 2011, Clinical Cancer Research.

Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.

C. Hudis, J. Baselga, V. Semiglazov, 2014 .

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results.

V. Semiglazov, X. Pivot, S. Chatterjee, 2018, European journal of cancer.

A Comparison of Proposed Biosimilar and Originator Filgrastim for the Prevention of Neutropenia in Patients with Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Phase III, Randomized, Double-Blind Trial (The PIONEER study)

K. Blackwell, N. Harbeck, V. Semiglazov, 2014 .

Abstract GS4-01: Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane

P. Fasching, Sung-Bae Kim, M. Piccart, 2021 .

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

R. Gelber, L. Pusztai, J. Baselga, 2012, The Lancet.

Breast cancer biomarker (ER, PR, HER2) changes in the phenotype after neoadjuvant treatment

V. Semiglazov, V. Chirsky, T. Semiglazova, 2018, Medical Council.

Biomarkers as potential predictors of pathologic complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC)

L. Pusztai, J. Baselga, W. Eiermann, 2008 .

Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis

J. Baselga, W. Eiermann, A. Lluch, 2007 .

Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

V. Semiglazov, X. Pivot, S. Chatterjee, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens.

V. Semiglazov, E. Bayever, S. Tjulandin, 2014, Clinical breast cancer.

Aromatase in breast cancer tissue — localization and relationship with reproductive status of patients

V. Semiglazov, O. Ivanova, A. Larionov, 2005, Journal of Cancer Research and Clinical Oncology.

Current evaluation of the contribution of self-examination to secondary prevention of breast cancer

V. Semiglazov, V. Moiseyenko, 1987, European Journal of Epidemiology.

Breast self-examination for the early detection of breast cancer: a USSR/WHO controlled trial in Leningrad.

V. Semiglazov, V. Moiseenko, V. Semiglazov, 1987, Bulletin of the World Health Organization.

[The role of self-examination in early diagnosis of breast cancer].

V. Semiglazov, V. Moiseenko, 1986, Voprosi onkologii.

Study of the role of breast self-examination in the reduction of mortality from breast cancer. The Russian Federation/World Health Organization Study.

V. Semiglazov, V. Moiseyenko, É. A. Mikhailov, 1993, European journal of cancer.

Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P).

A. Lluch, V. Semiglazov, Y. Im, 2015 .

Control of resection margins after neoadjuvant systemic therapy in breast-conserving surgery in breast cancer patients

V. Semiglazov, T. Semiglazova, A. Chernaya, 2023, HERALD of North-Western State Medical University named after I.I. Mechnikov.

Experience of Application of the International Classification of Functioning (ICF) in Assessment of the Need for Rehabilitation of Patients with Operated Breast Cancer

V. Semiglazov, T. Semiglazova, P. Krivorotko, 2021, Bulletin of Rehabilitation Medicine.

[Work experience of the WHO International Reference Center in assessing the effectiveness of self-examination for the early diagnosis of breast cancer (results of 2 years' research)].

V. Semiglazov, V. Moiseenko, I. K. Seleznev, 1988, Voprosy onkologii.

Comparative analysis of the effectiveness of neoadjuvant systemic therapy and primary surgical treatment of patients with BRCA-associated triple-negative T1 breast cancer

A. Sokolenko, E. Imyanitov, V. Semiglazov, 2023, HERALD of North-Western State Medical University named after I.I. Mechnikov.

Tamoxifen therapy for cyclical mastalgia: dose randomized trial

V. Semiglazov, 1997 .

Expression of estrogen receptors-α and -β in primary breast neoplasms and tumors exposed to neoadjuvant hormonal therapy

V. Semiglazov, E. Tsyrlina, L. Bershtein, 2004, Bulletin of experimental biology and medicine.

Expression of estrogen receptors-alpha and -beta in primary breast neoplasms and tumors exposed to neoadjuvant hormonal therapy.

V. Semiglazov, E. Tsyrlina, L. Bershtein, 2004, Bulletin of experimental biology and medicine.

5,10 methylenetetrahydrofolic acid with fluorouracil as treatment for advanced breast cancer in patients who failed prior treatment with anthracyclines and taxanes: A phase II study

H. Gómez, V. Semiglazov, C. Martín, 2008 .

Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308))

E. Winer, J. Cuzick, J. Bergh, 2017 .

The role of breast self-examination in early breast cancer detection (results of the 5-years USSR/WHO randomized study in Leningrad)

V. Semiglazov, R. T. Popova, N. Migmanova, 1992, European Journal of Epidemiology.

[Interim results of a prospective randomized study of self-examination for early detection of breast cancer (Russia/St.Petersburg/WHO)].

V. Semiglazov, A. Manikhas, V. Moiseenko, 1999, Voprosy onkologii.

[Preliminary results of the Russia (St.Petersburg)/WHO program for the evaluation of the effectiveness of breast self-examination].

V. F. Azeev, V. Semiglazov, V. Moiseenko, 1996, Voprosy onkologii.

[Results of phase I study of the effectiveness of self-examination in a program of early detection of breast cancer].

V. Semiglazov, V. Moiseenko, R. T. Popova, 1985, Voprosy onkologii.

Cerebel (EGF111438): An Open Label Randomized Phase III Study Comparing the Incidence of CNS Metastases in Patients (PTS) with HER2+ Metastatic Breast Cancer (MBC), Treated with Lapatinib Plus Capecitabine (LC) Versus Trastuzumab Plus Capecitabine (TC)

M. Desilvio, V. Semiglazov, X. Pivot, 2012 .

487 Efficacy of first-line capecitabine plus bevacizumab in patients with ER/PgR-positive metastatic breast cancer (MBC) and those previously treated with hormone therapy

V. Semiglazov, V. Diéras, S. Tjulandin, 2010 .

N3 category in the TNM classification of breast cancer needs to be defined more precisely

V. Semiglazov, 1997 .

Abstract P3-14-21: Phase II Study of Single Agent Trifunctional Antibody Ertumaxomab (Anti-HER-2 & Anti-CD3) in HER-2 Low Expressing Hormone-Refractory Advanced Breast Cancer Patients (ABC)

F. Cardoso, V. Semiglazov, L. Dirix, 2010 .

Preoperative hormonal therapy vs chemotherapy in postmenopausal ER-positive breast cancer patients

V. Semiglazov, L. Berstein, E. Ziltsova, 2004 .

Adjuvant therapy in premenopausal women with hormone-dependent breast cancer

V. Semiglazov, V. Y. Lifanova, V. S. Appolonova, 2018, Medical Council.

Effects of fulvestrant in premenopausal women with oestrogen receptor-positive primary breast cancer

V. Semiglazov, J. Robertson, J. Gee, 2004 .

Phase III trial of non-pegylated liposomal doxorubicin (M) in combination with trastuzumab (T) and paclitaxel (P) in HER2+ metastatic breast cancer (MBC).

C. Hudis, J. Baselga, V. Semiglazov, 2013 .

Hormone-metabolic status in moderately smoking breast cancer patients.

V. Semiglazov, O. Ivanova, L. Berstein, 1997, Acta oncologica.

Endocrine Metabolic Disorders in Patients with Breast Cancer, Carriers of BRCA1 Gene Mutations

E. Imyanitov, V. Semiglazov, L. Berstein, 2012, Bulletin of Experimental Biology and Medicine.

First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study.

M. Espié, N. Bogdanova, V. Semiglazov, 2012 .

RECIST for Response (Clinical and Imaging) in Neoadjuvant Clinical Trials in Operable Breast Cancer.

V. Semiglazov, 2015, Journal of the National Cancer Institute. Monographs.

Metabolic Immunodepression and Metabolic Immunotherapy

S. N. Fedorov, V. Semiglazov, I. K. Seleznev, 1982 .

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

R. Gelber, L. Pusztai, J. Baselga, 2012, The Lancet.

Neoadjuvant (Preoperative) Therapy in Breast Cancer

V. Semiglazov, V. Semiglazov, 2013 .

TiLoop Bra Assisted Breast Reconstruction - Our Experience.

V. Semiglazov, A. Bessonov, P. Krivorotko, 2021, Chirurgia.

Neoadjuvant systemic therapy for breast cancer

V. Semiglazov, 2012 .

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

R. Gelber, J. Baselga, U. Dafni, 2011, The Lancet. Oncology.

Pegylated liposomal doxorubicin (PLD) plus docetaxel significantly improves time to progression (TTP) compared with docetaxel (D) monotherapy in patients with advanced breast cancer (ABC) treated with adjuvant anthracycline: results from a randomized phase 3 study.

N. Bogdanova, J. Sparano, V. Semiglazov, 2009 .